Consistent with lower immunosuppression as an important precondition to promote the induction of tumor-directed T-cell responses, we observed an increase in tumor-infiltrating CD8 T cells 10 days after therapy initiation and a modified CD8/CD4 ratio in favor of CD8 T cells (Fig. 3e). The gene discussed is CD4; the disease is neoplasm.